AITRICS (CEO Gwangjun Kim), a medical artificial intelligence (AI) company, announced on the 10th that it participated in the '2025 HIMSS Global Health Conference & Exhibition' (HIMSS 2025) held in Las Vegas, USA from March 3rd to 6th.
The HIMSS Global Health Show is the most prestigious international event related to healthcare information and communication technology, hosted by the Healthcare Information and Management Systems Society (HIMSS) in the United States.
At this exhibition, AITRICS introduced 'AITRICS-VC (Vital Care),' an AI solution that predicts the deterioration of patient conditions. The company emphasized the excellent clinical effectiveness of Vital Care that has been accumulated in Korea by revealing the results of six clinical studies, including prospective studies and real-world data studies, along with the function that Vital Care can predict the risk of various indications such as sepsis and death in the early stage for the first time in Korea.
In addition, the fact that the company obtained FDA 510(k) certification last year has attracted the attention of several medical institutions at home and abroad, and it has decided to continue additional joint research by seeking business discussions with medical professionals.
AITrix CEO Kim Gwang-jun said, “VitalCare, which recently received FDA approval, has become an opportunity to more effectively promote the excellence of our products in the US market at this year’s HIMSS 2025 and make further progress in entering the US market.” He added, “We will fully introduce the clinical effectiveness of VitalCare to the global medical field beyond Korea and actively attack the global market through cooperation with US medical institutions.”
Meanwhile, AITRIX's Vital Care is currently being introduced and actively used in over 90 hospitals in Korea.
- See more related articles
You must be logged in to post a comment.